Sofinnova Partners
VC Fund
Paris, France
Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage.The firm manages over €2 billion of assets dedicated to life science investing and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential topositively impact its collective future. It invests in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations with a focus on Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. They sit on the boards of their portfolio companies and play an active role from the formation phase alongside entrepreneurs.It was headquartered in Paris, Ile-de-France in 1972.
- Total investments:
- 353
- Last investment:
- Lead investor:
- 47%
- Fund size:
- $755M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Sofinnova Partners invests in
Stages Sofinnova Partners invests in
Countries Sofinnova Partners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 19 contacts → | |||
Round size
- Series A
- $7M–$70M
- Series B
- $10M–$105M
- Series C
- $12M–$100M
Investment Focus
Industry
- Biotechnology 122 (35%)
- Health Care 70 (20%)
- Medical 48 (14%)
- Therapeutics 45 (13%)
- Pharmaceutical 38 (11%)
Stage
- Series A 94 (27%)
- Series B 66 (19%)
- Series C 42 (12%)
- Seed 28 (8%)
- Venture - Series Unknown 17 (5%)
Country
- France 51 (14%)
- United States 44 (12%)
- United Kingdom 25 (7%)
- Switzerland 12 (3%)
- Italy 10 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alain Tingaud
Venture Partner
|
Venture Partner | Total investments: 5 | Find email | |
Cedric Moreau
Partner
|
Partner | Total investments: 9 | Find email | |
Dominique Verdier
Operations
|
Operations | Total investments: 0 | Find email | |
Edward Kliphuis
Partner
|
Partner | Total investments: 16 | Find email | |
Jacques Theurillat
Partner, Crossover fund
|
Partner, Crossover fund | Total investments: 0 | Find email | |
| See all 19 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| HighLife is a company focused on Transcatheter Mitral Valve Replacement (TMVR). The technology is intended for treatment of patients suffering from mitral valve regurgitation and is currently in a stage of clinical evaluation.The company was co-founded in 2010 by Mr. Georg Börtlein, President & CEO. The intent is to provide a minimallyinvasive prosthetic mitral valve that is implanted on a beating heart, while preserving the native valve structure and respecting the surrounding anatomy. Ease and safety of use and delivery are key elements of the HighLife technology. | $90M / Venture - Series Unknown / Sep 22, 2026 | ||
| EnginZyme is a biotechnology company that specializes in biocatalysis. It creates products for easy and cost-efficient implementation of biocatalytic processes and helps the chemical industry transition to a sustainable way of operating.The company is driven by a mission to make biocatalysis the first choice for chemical process designersworldwide. | $7.6M / Venture - Series Unknown / Sep 22, 2026 | ||
| Google Analytics is a web analysis service provided by Google. Google utilizes the data collected to track and examine the use of www.mironid.com, to prepare reports on its activities and share them with other Google services. Google may use the data collected to contextualize and personalize the ads of its own advertising network. | $45.9M / Series B / Aug 05, 2026 | ||
| Bionyra Pharma is a clinical-stage biopharmaceutical startup developing next-generation biologics for serious immune-mediated inflammatory diseases. | $165M / Series A / Jun 22, 2026 | ||
| Ingenix is building an AI Co-pilot for generating real-time hypotheses on clinical endpoints values and adverse events. | $15.1M / Seed / Jun 03, 2026 | ||
| P2 Science a venture-backed, renewable specialty chemicals company, co-founded by Yale scientists, a chemical industry CEO and Elm Street Ventures, an early-stage venture fund. P2 Science has developed a unique process technology for converting renewable feedstocks—including vegetable oils—into high-value, specialty chemicals. These includeflavor, fragrance and cosmetics ingredients. Many of their products are today available only from petrochemical sources. Among the first products to be produced by P2 are vegetable-derived, cost-effective versions of current petrochemical fragrance ingredients. Major users and formulators of specialty chemicals have a strong interest in substituting renewable for petrochemical ingredients. Patrick Foley, a Yale graduate of the PhD program in Environmental Engineering, is P2′s Chief Scientific Officer. Neil Burns, an executive with 20+ years experience in the specialty chemical industry, is the company’s CEO. P2 has a laboratory in New Haven, CT to support this technology’s development and commercialization, as well as partnerships with major companies at a number of points along the supply chain. | $23M / May 26, 2026 | ||
| CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. | $220M / Series D / May 06, 2026 | ||
| Signadori Bio is the next-generation cellular immunotherapy for cancer cure.This has culminated in the creation of a groundbreaking biotech venture in the cell and gene space that is set to advance innovative approaches in oncology. | $13M / Seed / May 06, 2026 | ||
| Biotalys is an Agricultural Technology (AgTech) company that employs its proprietary Agrobody technology platform to develop crop and food protection products. The company develops a new generation of protein-based biocontrol solutions, shaping the future of sustainable and safe food supply. Biotalys' unique protein-based biocontrols combinethe high-performance characteristics of chemicals with the clean safety profile of biologicals, making them ideal crop protection agents for both pre- and post-harvest applications.It was incorporated in 2013 and is based in the Biotech hub in Ghent, Belgium. | $14.1M / Post-IPO Equity / May 06, 2026 | ||
| AblaCare develops an innovative solution for Polycystic Ovary Syndrome (PCOS) related infertility, designed to provide patients with a more natural and less medicalised pregnancy experience.AblaCare aims to restore ovulation in PCOS patients through a simple, one-time, durable, minimally invasive treatment. AblaCare's procedure is donetransvaginally, under ultrasound guidance, and does not require general anesthesia. The technique can be performed in the clinic setting using the same minimally invasive access commonly used by fertility physicians for IVF. | $11.6M / Venture - Series Unknown / Mar 10, 2026 | ||
| See all 353 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Sofinnova Partners invest in?
Sofinnova Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 353 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Sofinnova Partners's check size?
Sofinnova Partners typically joins rounds of $7M–$70M at Series A, $10M–$105M at Series B and $12M–$100M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sofinnova Partners participates in.
How do I contact Sofinnova Partners?
Public channels for Sofinnova Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Sofinnova Partners?
The team at Sofinnova Partners includes Alain Tingaud (Venture Partner), Cedric Moreau (Partner) and Dominique Verdier (Operations), among 19 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
